Prevalence and incidence of hepatitis C virus infection among young adult injection drug users

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue SUPPL., 1998, Pages

  Garfein, Richard S ^a   Doherty, Meg C ^a   Monterroso, Edgar R ^b   Thomas, David L ^a,c   Nelson, Kenrad E ^a,c   Vlahov, David ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C virus; Initiation; Injection drug use; Seroincidence; Seroprevalence; Syringe sharing; Young adult

Indexed keywords

COCAINE;

ADULT; ARTICLE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; STATISTICAL ANALYSIS; SYRINGE;

HEPATITIS C VIRUS;

EID: 0032125409     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802001-00004     Document Type: Article

References (45)

1. van den Hoek JA, van Haastrecht HJ, Goudsmit J, et al. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990;162:823-6.
2. Rezza G, Sagliocca L, Zaccarelli M, et al. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis 1996;28: 27-9.
3. Crofts N, Hopper JL, Bowden DS, et al. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993;159:237-41.
4. Woodfield DG, Harness M, Rix-Trott K, et al. Identification and genotyping of hepatitis C virus in injectable and oral drug users in New Zealand. Aust NZJ Med 1994;24:47-50.
5. Patti AM, Santi AL, Pompa MG, et al. Viral hepatitis and drugs: a continuing problem. Int J Epidemiol 1993;22:135-9.
6. Chetwynd J, Brunton C, Blank M, et al. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. N Z Med J 1995;108:364-6.
7. Majid A, Holmes R, Desselberger U, et al. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. J Med Virol 1995;46:48-51.
8. Zeldis JB, Jain S, Kuramoto IK, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992;156:30-5.
9. Westh H, Worm AM, Jensen BL, et al. Hepatitis C virus antibodies in homosexual men and intravenous drug users in Denmark. Infection 1993;21:115-7.
10. Donahue JG, Nelson KE, Munoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991; 134:1206-11.
11. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995;74:212-20.
12. Lee SD, Chan CY, Wang YJ, et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology 1991;13:830-3.
13. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. J Infect Dis 1995;171:768-75.
14. van Beek I, Buckley R, Stewart M, et al. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 1994;70:321-4.
15. Robinson GM, Reynolds JN, Robinson BJ. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users. N Z Med J 1995;108:103-5.
16. Nishioka K. Epidemiological studies on hepatitis C virus infection: detection, prevalence, exposure and prevention. Intervirology 1994;37:58-67.
17. Bell J, Batey RG, Farrell GC, et al. Hepatitis C virus in intravenous drug users. Med J Aust 1990;153:274-6.
18. Smyth R, Keenan E, Dorman A, et al. Hepatitis C infection among injecting drug users attending the National Drug Treatment Centre. Ir J Med Sci 1995;164:267-8.
19. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users - the prevalence of hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;655-61.
20. Battjes RJ, Leukefeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992;18:263-73.
21. Hser YI, Anglin MD, McGlothlin W. Sex differences in addict careers. 1. Initiation of use. Am J Drug Alcohol Abuse 1987;13: 33-57.
22. Nurco DN, Bonito AJ, Lerner M, et al. Studying addicts over time: methodology and preliminary findings. Am J Drug Alcohol Abuse 1975;2:183-96.
23. Koester SK, Hoffer L. "Indirect sharing": additional HIV risks associated with drug injection. AIDS Publ Policy J 1996;Summer:100-5.
24. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5.
25. van Ameijden EJ, van den Hoek JA, Mientjes GH, et al. A longitudinal study on the incidence and transmission patterns of HIV. HBV. and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993;9:255-62.
26. Chamot E, de Saussure P, Hirschel B, et al. Incidence of hepatitis C. hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS 1992;6:430-1.
27. Crofts N, Stewart T, Hearne P, et al. Spread of bloodborne viruses among Australian prison entrants. BMJ 1995;310:285-8.
28. Hagan H, Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health 1995;85:1531-7.
29. Nelson KE, Vlahov D, Cohn S, et al. Human immunodeficiency virus infection in diabetic intravenous drug users. JAMA 1991;266: 2259-61.
30. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996;348:987-91.
31. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:175-6.
32. Gostin LO, Lazzarini Z, Jones TS, et al. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. A national survey on the regulation of syringes and needles. JAMA 1997;277:53-62.
33. Groseclose SL, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers - Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:82-9.
34. Valleroy LA, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales - Connecticut. 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:73-81.
35. Chaisson RE, Bacchetti P, Osmond D, et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261:561-5.
36. Novick DM, Trigg HL, Des Jarlais DC, et al. Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J Med Virol 1989;29:181-5.
37. Meandzija B, O'Connor PG, Fitzgerald B, et al. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend 1994;36:109-13.
38. Nemoto T. Patterns of cocaine use and HIV infection among injection drug users in a methadone clinic. J Subst Abuse 1994;6: 169-78.
39. Battjes RJ, Pickens RW, Haverkos HW, et al. HIV risk factors among injecting drug users in five US cities. AIDS 1994;8:681-7.
40. Joe GW, Simpson DD. HIV risks, gender, and cocaine use among opiate users. Drug Alcohol Depend 1995;37:23-8.
41. Bux DA, Lamb RJ, Iguchi MY. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend 1995; 37:29-35.
42. Anthony JC, Vlahov D, Nelson KE, et al. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol 1991;134:1175-89.
43. Doherty MC, Garfein RS, Monterroso E, et al. Younger age of initiating injecting drug use is associated with risky behavior and HIV infection in short-term injectors [abstract Mo.C.464]. Presented at the XI International Conference on AIDS. Vancouver, Canada, July 1996.
44. Greenfield L, Bigelow GE, Brooner RK. HIV risk behavior in drug users: increased blood "booting" during cocaine injection. AIDS Educ Prev 1992;4:95-107.
45. Hudgins R, McCusker J, Stoddard A. Cocaine use and risky injection and sexual behaviors. Drug Alcohol Depend 1995;37:7-14.